BCT 1702 (CHARIOT): Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment.

Trial Profile

BCT 1702 (CHARIOT): Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms CHARIOT
  • Most Recent Events

    • 28 Sep 2017 Last checked against Australian New Zealand Clinical Trials Registry
    • 26 Sep 2017 Planned number of patients changed from 30 to 33.
    • 26 Sep 2017 Planned End Date changed from 31 Oct 2021 to 31 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top